Brief: Quantum Genomics Enrolls First Patient In REFRESH Study
July 8 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* RECRUITMENT OF FIRST PATIENT IN REFRESH STUDY, PHASE 3
PIVOTAL
STUDY IN HARD-TO-TREAT WITH FIRIBASTAT HYPERTENTION
* STUDY WILL RECRUIT 750 PATIENTS WITH RESULTS EXPECTED
MID-2023
Source text: https://bit.ly/3xpL7vB
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study